EuCorVac-19

BIOLOGICAL3 trials

Sponsors

EuBiologics Co.,Ltd

Conditions

COVID-19

Phase 1

Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

CompletedNCT04783311

EuBiologics Co.,LtdCOVID-19

Start: 2021-02-23End: 2022-09-27Updated: 2023-05-19

Phase 3

A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

CompletedNCT05572879

EuBiologics Co.,LtdCOVID-19

Start: 2022-10-01End: 2024-02-09Updated: 2024-06-17

A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older

CompletedNCT05603052

EuBiologics Co.,LtdCOVID-19

Start: 2022-07-11End: 2024-01-15Updated: 2025-01-07

Related Papers

Year-Long Antibody Response to the EuCorVac-19 SARS-CoV-2 Vaccine in Healthy Filipinos

Vaccines2025-07-221 citations

Interim safety and immunogenicity analysis of the EuCorVac‐19 COVID‐19 vaccine in a Phase 3 randomized, observer‐blind, immunobridging trial in the Philippines

Journal of Medical Virology2024-09-0112 citations

One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects.

2023-11-0714 citations

Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

BMC Medicine2022-11-3033 citations